Metrics as of 10/17/2026, 08:48 AM (Berlin time), refresh in progress.
Delcath Systems Stock
Delcath Systems, Inc.
Company data
- Sector
- Healthcare
- Industry
- Medical - Devices
- Country
- United States
- CEO
- Gerard J. Michel
- Employees
- 156
- Market cap
- $489 M
- IPO
- 03/05/2018
Delcath Systems, Inc. is an interventional oncology firm operating in the United States and Europe, dedicated to developing treatments for both primary and secondary liver cancers. Its leading investigational product is the HEPZATO KIT, a unique hepatic delivery system for melphalan that targets high-dose chemotherapy…
Delcath Systems stock: price history
1D
-4.9%
1W
-8.3%
1M
-13.2%
6M
+29.7%
YTD
+39.4%
1Y
+13.9%
2Y
+48.1%
5Y
+49.6%
10Y
–
Next earnings date
Next earnings date
03/11/2026 (in 17 days)
Volatility around earnings
~4% weaker price swings than usual
Delcath Systems stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Robust business model that benefits noticeably from at least one megatrend.
1 more assignment (Enabler/Second row) Pro-only.
Delcath Systems, Inc. operates in the field of interventional oncology, focusing on treatments for primary and secondary liver cancer. The company develops specialized systems for targeted delivery of chemotherapy agents to the liver, reducing systemic drug exposure for patients and minimizing side effects. With the HEPZATO Kit and the CHEMOSAT Hepatic Delivery System, the company offers innovative medical solutions. While portions of product development in the United States remain in clinical trials, the system is already being marketed as a medical device in Europe. The business model is based entirely on product sales.
- Revenue model
- Hardware sales
- Recurring revenue
- None
- Pricing power
- Strong
- Moat
- Narrow
- Moat type
- Brand / IP
- Capital intensity
- High
- Customer concentration
- Unknown
Ask the agents about Delcath Systems
Analyst assessment of Delcath Systems
PRICE TARGET LOW
US$17.00
CONSENSUS
US$24.50
MEDIAN
US$24.50
PRICE TARGET HIGH
US$32.00
0
STRONG BUY
8
BUY
2
HOLD
1
SELL
0
STRONG SELL
11
TOTAL · Buy
As of: 07/08/2026
Delcath Systems stock metrics
P/E
1,280
P/B
4.17
EV/EBITDA
247.21
RETURN ON EQUITY
2.2%
NET MARGIN
9.2%
DEBT/EQUITY
0.02
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
82.9%
FLOAT SHARES
28,777,793
AVG. DAILY VOLUME (30D)
335,458
Insider transactions (SEC)
Rosalind Advisors, Inc.
Rosalind Advisors, Inc.
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Delcath Systems stock
What does Delcath Systems do?
Delcath Systems, Inc. is a company in the Healthcare sector, Medical - Devices industry, headquartered in United States.
The CEO is Gerard J. Michel, the company employs around 156 people.
The IPO was on 03/05/2018; the stock trades on NASDAQ under the ticker DCTH.
What do analysts say about Delcath Systems stock?
11 analysts rate the stock, the consensus is Buy (as of 07/08/2026).
The average price target is US$24.50, ranging from US$17.00 to US$32.00, with a median of US$24.50.
This is an external assessment, not a statement by Market Jury.
When does Delcath Systems report next?
The next earnings date is 03/11/2026.
Around past earnings, price swings were roughly -4% stronger than usual.
Does Delcath Systems pay a dividend?
No, Delcath Systems currently does not pay a dividend.
Which stocks are comparable to Delcath Systems?
Comparable stocks include Abbott Laboratories, Stryker, Boston Scientific, Edwards Lifesciences, DexCom, GE HealthCare Technologies, Zimmer Biomet Holdings and Align Technology.
How can I get Delcath Systems stock analyzed?
Clicking "Analyze stock" lets five strategies assess Delcath Systems against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.